Thyme Care Secures $97 Million Series D To Transform Cancer Care
By Amit Chowdhry ● Sep 29, 2025
Thyme Care, a leading innovator in value-based cancer care, has completed a $97 million Series D funding round. This funding demonstrates strong confidence from both existing and new strategic partners, bringing Thyme Care's total capital raised to $275 million. The continued support from current investors, including CVS Health Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures, highlights the established success and future potential of Thyme Care's approach. This round also saw the addition of key strategic investors, including Morgan Health, a division of JPMorganChase dedicated to employer-sponsored healthcare, along with Humana, Texas Oncology, and Memorial Hermann Health System, further solidifying Thyme Care's position within the healthcare landscape.